In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant ...

The technical backdrop, however, points to caution. Seeking Alpha's momentum page flags Moderna as overbought on its relative strength index, with RSI levels indicating the stock has sprinted ahead of ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership with Merck, announced positive results from a five-year ...

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

Moderna (MRNA) stock hits a 52-week high to extend its YTD rally following back-to-back years of declines. Read more here.

Hongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw MaterialsSingapore, January 12, 2026: Hongene Biotech today announced the receipt of a grant from the Gates Foundation to ...

Japan biotech xFOREST Therapeutics is teaming up with a drug discovery solutions provider in a research pact aiming to develop new RNA structure-targeted small molecule therapeutics, including mRNA ...

Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing ...

Hongene Biotech receives grant from Gates Foundation to develop and expand global access to mRNA vaccine raw materials: Singapore Saturday, January 24, 2026, 11:00 Hrs [IST] Honge ...